NCT04892251 Ketamine Assisted Psychotherapy for Opioid Use Disorder
| NCT ID | NCT04892251 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | University of Utah |
| Condition | Opioid-use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2021-05-20 |
| Primary Completion | 2023-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2021-05-20 with a primary completion date of 2023-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot clinical trial aims to assess the preliminary efficacy of ketamine as an adjunct for a mindfulness-based intervention for opioid use disorder.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of Opioid Use Disorder 2. Receiving OUD treatment with a buprenorphine formulation Exclusion Criteria: 1. Previous experience with a mindfulness-based intervention program 2. Pregnancy 3. Any serious medical, mental, or cognitive issue that prevents successful participation in a mindfulness-based group treatment program 4. Prior use of ketamine other than as prescribed by a physician 5. Any of the following medical conditions Blood Vessel Disease Heart Valve Disease Heart Failure Class 2 or Above Heart Disease Pregnancy/Breastfeeding Arteriovenous Malformation History of Intracranial Bleeding or Stroke History of Seizures Hypoxia defined by current need for supplemental oxygen Liver Disease History of allergic reaction to Ketamine Dementia (moderate-severe) History of Psychotic Disorder, Bipolar Disorder, or Personality Disorder Dissociative Identity Disorder
Contact & Investigator
Eric L Garland
PRINCIPAL INVESTIGATOR
University of Utah
Frequently Asked Questions
Who can join the NCT04892251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid-use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04892251 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04892251 currently recruiting?
Yes, NCT04892251 is actively recruiting participants. Contact the research team at eric.garland@socwk.utah.edu for enrollment information.
Where is the NCT04892251 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT04892251 clinical trial?
NCT04892251 is sponsored by University of Utah. The principal investigator is Eric L Garland at University of Utah. The trial plans to enroll 60 participants.